ライフサイエンスコーパス: thrombolytics

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 use of the limited effectiveness of existing thrombolytics.

2 ing vessel recanalization with intraarterial thrombolytics.

3 file of abciximab was observed between the 2 thrombolytics.

4 tracerebral haemorrhage after treatment with thrombolytics (2 [7%] telemedicine vs 2 [8%] telephone,

5 from baseline to the fifth year: intravenous thrombolytics (42.09% versus 72.84%), early antithrombot

6 tion, and the concomitant use of intravenous thrombolytics, among others.

7 wo hundred fifty-eight AMI patients from the Thrombolytics and Myocardia Infarction phase 7 and Globa

8 ilities, patients who received intracoronary thrombolytics, and those who received no medications wit

9 ral arterial access site, >6-Fr sheath size, thrombolytics, arterial dissection, fluoroscopy time >30

10 lready arrested, the difficulty of obtaining thrombolytics at the bedside rapidly enough to administe

11 We reported odds ratios (ORs) for use of thrombolytics, beta-blockers, ACE inhibitors, or aspirin

12 elevation myocardial infarction who receive thrombolytics, clopidogrel therapy confers broad benefit

13 bition in myocardial infarction treated with thromboLYtics (COMPLY) and COMplement inhibition in Myoc

14 d diagnosis of pulmonary embolism and use of thrombolytics during cardiopulmonary resuscitation may n

15 the lack of good data supporting the use of thrombolytics during resuscitation, the belief that thro

16 atments: coronary-artery reperfusion before, thrombolytics during, and beta-blockers, antiplatelet dr

17 Thrombolytics (eg, tissue-type plasminogen activator [tP

18 To increase the effective use of thrombolytics for acute stroke, the expertise of vascula

19 iximab in combination with administration of thrombolytics has been shown to improve epicardial and m

20 ng stroke recovery long after the window for thrombolytics has passed.

21 Clinically approved thrombolytics have significant drawbacks, including blee

22 rdiopulmonary arrest and discuss the role of thrombolytics in cardiopulmonary resuscitation.

23 ted heparin was administered in 33 (87%) and thrombolytics in four (11%).

24 The use of thrombolytics in the treatment of vertebrobasilar occlus

25 l patient population, those not treated with thrombolytics (n = 228,512) and those given thrombolytic

26 assess their suitability for treatment with thrombolytics, on the basis of standard criteria.

27 enzyme elevation, some argue for the use of thrombolytics or catheter thrombectomy even for hemodyna

28 No patient received thrombolytics or surgical evacuation of clot.

29 By multivariable analysis, thrombolytics, prior myocardial infarction, advancing ag

30 coronary syndromes who are not eligible for thrombolytics reduced the composite of recurrent ischemi

31 gment elevation AMI and contraindications to thrombolytics should be strongly considered.

32 Use of thrombolytics was associated with lower all-cause mortal

33 thrombolytics (n = 228,512) and those given thrombolytics were 10.4%, 12.9% and 5.9%, respectively (

34 Intravenous thrombolytics were used at an overall rate of 25% (31 [2

35 Thrombolytics were used at presentation in 19 (35%) pati

36 imaging and new clinical trials that combine thrombolytics with other pharmacological and interventio

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。